ChronoScale (CHRN) Q2 2025 earnings summary

Executive summary

• Revenue for Q2 2025 was $2.1M, down 58% year-over-year, mainly due to delayed or lower Enterprise Health device sales in the Americas, partially offset by increased Personal Health device sales, including over 50% growth in Ekso Indego Personal.

• Net loss for the quarter was $2.7M ($1.24 per share), a 12% increase from Q2 2024.

• Gross margin declined to 40% from 53% year-over-year, reflecting lower Enterprise Health sales and higher shipping or fixed costs.

• The company is expanding Personal Health sales, leveraging recent Medicare reimbursement approval for Ekso Indego Personal and new distribution partnerships.

• Strategic initiatives included AI integration and the launch of an educational platform for neurological rehabilitation.

Financial highlights

• Q2 2025 revenue: $2.1M (Q2 2024: $5.0M); six-month revenue: $5.4M (2024: $8.7M).

• Net loss Q2 2025: $2.7M ($1.24/share) (Q2 2024: $2.4M, $1.99/share); six-month net loss: $5.6M (2024: $5.8M).

• Gross profit Q2 2025: $0.8M (Q2 2024: $2.6M); gross margin: 40% (2024: 53%).

• Operating expenses Q2 2025: $4.8M, down 4% year-over-year; sales and marketing: $1.7M, R&D: $0.9M, G&A: $2.3M.

• Cash and restricted cash at June 30, 2025: $5.2M; unrestricted cash: $3.2M.

Outlook and guidance

• Management expects operating losses and negative cash flows to continue, with current cash projected to fund operations into Q4 2025.

• Additional financing is being sought; if not secured, cost reductions and project delays may be necessary.

• Management expects to recover deferred Enterprise Health sales in the second half of 2025 and anticipates continued strong growth from Personal Health products.